Single-center phase 2 study of niraparib for previously treated advanced melanoma with homologous recombination pathway gene mutations

Up to one third of melanomas harbor at least one molecular aberration in the homologous recombination (HR) pathway, leading to HR deficiency. A phase 2 trial at Sutter California Pacific Medical Center (San Francisco) evaluated niraparib monotherapy for previously treated metastatic melanoma with HR pathway gene mutations. Partial response and stable disease were seen in 14% and 50% of patients, respectively. The median progression-free survival was 16 weeks. None of the patients with uveal melanoma responded, whereas among patients with nonuveal melanoma 20% achieved partial respons and 50% achieved stable disease/. There were no unexpected adverse events related to niraparib. The authors conclude that niraparib monotherapy had promising activity for previously treated nonuveal metastatic melanoma with HR gene mutations.